Chiasma Inc (NASDAQ:CHMA) – Piper Jaffray Companies boosted their FY2019 earnings estimates for shares of Chiasma in a report issued on Tuesday, November 5th. Piper Jaffray Companies analyst E. Tenthoff now expects that the biotechnology company will post earnings per share of ($1.03) for the year, up from their previous estimate of ($1.09). Piper Jaffray Companies has a “Overweight” rating and a $11.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Chiasma’s Q4 2019 earnings at ($0.23) EPS, Q1 2020 earnings at ($0.23) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.30) EPS, Q4 2020 earnings at ($0.34) EPS, FY2020 earnings at ($1.14) EPS, Q1 2021 earnings at ($0.28) EPS, Q2 2021 earnings at ($0.24) EPS, Q3 2021 earnings at ($0.19) EPS and FY2021 earnings at ($0.86) EPS.
Several other equities analysts also recently weighed in on CHMA. Zacks Investment Research downgraded Chiasma from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. Brookline Capital Management restated a “buy” rating on shares of Chiasma in a research report on Wednesday, July 24th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Chiasma in a research report on Thursday. ValuEngine downgraded Chiasma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Cantor Fitzgerald set a $18.00 price objective on Chiasma and gave the stock a “buy” rating in a research report on Friday, September 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $12.30.
Shares of NASDAQ CHMA traded down $0.09 during midday trading on Friday, hitting $5.26. The stock had a trading volume of 13,516 shares, compared to its average volume of 159,114. The company has a market capitalization of $225.72 million, a PE ratio of -4.10 and a beta of 1.19. The stock has a 50 day simple moving average of $5.14 and a 200-day simple moving average of $5.95. Chiasma has a 1 year low of $2.11 and a 1 year high of $9.25.
Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01.
Large investors have recently bought and sold shares of the stock. Strs Ohio purchased a new position in Chiasma during the 2nd quarter worth approximately $560,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Chiasma during the 2nd quarter valued at $100,000. Altshuler Shaham Ltd grew its holdings in shares of Chiasma by 143.2% during the 2nd quarter. Altshuler Shaham Ltd now owns 101,953 shares of the biotechnology company’s stock valued at $762,000 after acquiring an additional 60,026 shares in the last quarter. Wells Fargo & Company MN purchased a new position in shares of Chiasma during the 2nd quarter valued at $237,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Chiasma by 242.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,139 shares of the biotechnology company’s stock valued at $545,000 after acquiring an additional 51,806 shares in the last quarter. Institutional investors and hedge funds own 53.00% of the company’s stock.
In other news, Director Scott Minick purchased 9,818 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average cost of $5.19 per share, for a total transaction of $50,955.42. Following the completion of the purchase, the director now owns 62,531 shares of the company’s stock, valued at $324,535.89. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Roni Mamluk sold 50,000 shares of Chiasma stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $5.59, for a total value of $279,500.00. Following the completion of the transaction, the director now owns 50,000 shares of the company’s stock, valued at $279,500. The disclosure for this sale can be found here. Insiders have purchased a total of 17,268 shares of company stock valued at $96,823 over the last three months. 8.30% of the stock is currently owned by insiders.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Article: Initial Public Offering (IPO)
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.